MedTrace Logo

The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy

NCT03073031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2023-01-26

No results posted yet for this study

Summary

This study evaluates if melanoma patients who report their side effects to immunotherapy weekly by the use of ePRO-CTCAE will experience an overall reduction of grade 3 and 4 events with 50% compared to routine monitoring carried out every 3 weeks.

Conditions

  • Adverse Effects

Interventions

DEVICE

Tablet: Samsung Galaxy Tab A

Sponsors & Collaborators

  • REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Danish Cancer Society

    collaborator OTHER

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Laerke K. Tolstrup, MD · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2019-11-01
Completion
2019-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03073031 on ClinicalTrials.gov